| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6176349 | European Urology | 2016 | 7 Pages |
Abstract
There is a strong rationale for testing mTOR inhibitors with a broader spectrum of activity than everolimus in metastatic clear cell renal cell carcinoma. AZD2014 is such an agent, but in this study, it was inferior to everolimus despite its attractive toxicity profile.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Thomas Powles, Matthew Wheater, Omar Din, Thomas Geldart, Ekaterini Boleti, Andrew Stockdale, Santhanam Sundar, Angus Robinson, Imtiaz Ahmed, Akhila Wimalasingham, Wendy Burke, Shah-Jalal Sarker, Syed Hussain, Christy Ralph,